The 10 Companies Booming in Healthcare Sector

OncoSnap® is a pioneering tumor tissue profiling test which screens for clinically
relevant somatic mutations of 130 genes in solid tumor tissues by using NGS
technologies, and offers FDA-approved therapies undergoing clinical trials.
Able to detect single nucleotide variations (SNVs), insertions and deletions (indels),
selected fusions and copy number alterations
OncoSnap BRCATM is a pioneering NGS-based tumor tissue profiling test which
screens for somatic mutations of BRCA1 and BRCA2 genes in solid tumor tissues.
This test is useful for assessing patients who are diagnosed with breast cancer,
ovarian cancer and prostate cancer on whether they could be benefited from selected
PARP inhibitor treatments.
OncoSnap NonetTM screens for 9 genes in tumor tissue samples, intending to aid
physicians to identify multi-genetic biomarkers for potential treatment options for
primary diagnosed non-small-cell lung cancer patients.
PD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay using
Monoclonal Mouse Anti-PD-L1, Clone 22C3 to detect PD-L1 protein in FFPE tissue
specimens using EnVision FLEX visualization system on Autostainer Link 48. It
detects PD-L1 expression with a dynamic range of tumor-positive (TPS) 0-100% and
combined positive score (CPS) 0-10+.
Cancers include lung cancer, gastric cancer, urothelial cancer, cervical cancer, etc.
EmbryoSafeTM screens all 24 chromosomes of IVF and ICSI embryos to detect
pathogenic chromosome copy number changes, including aneuploidy, mosaicism,
unbalanced translocations, and microduplications/microdeletions (> 10 Mb).
5. With respect to your distinctive products and services, how have you helped bring positive developments in the
healthcare industry?
Sanomics contributed to provide genomic tests to help doctors decide personalized cancer solutions for patients. We keep
providing solutions to tackle with the pain points in current cancer management process. For example, Sanomics is the
first local private company in Hong Kong to adopt liquid biopsy, a non-invasive cancer screening technology that spares
patients from the painful tissue biopsy, a traditional procedure of collecting tissue samples from tumors. Another example
is that tissue samples often run outs before answering all the clinical questions that guide treatment selection, therefore,
TM
by launching OncoSnap Nonet , this test can screen for 9 genes in tumor tissue samples to make best use of tissue.
6. Are there any social activities that your company organizes to uplift healthcare space?
To raise the public awareness of adopting genomic test in cancer management, Sanomics organizes workshops and
seminars for healthcare professionals and general public. We also co-operate with our strategic partners, such as
18
| June 2019 |